Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: Efficacy and concomitant cyclosporin A

Mycoses

Volumn 50, Issue SUPPL. 1, 2007, Pages 24-37

  Morrissey, C O ^a,b,c   Slavin, M A ^c,d,e   O'Reilly, M A ^f   Daffy, J R ^f,g   Seymour, J F ^h   Schwarer, A P ^a,b,f   Szer, J ^e  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f BOX HILL HOSPITAL   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Caspofungin; Cyclosporin A; Efficacy; Haematological malignancies; Invasive aspergillosis; Stem cell transplantation

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; CASPOFUNGIN; CYCLOSPORIN A; ITRACONAZOLE; VORICONAZOLE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; AUSTRALIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER TOXICITY; MALE; MEDICAL RECORD; MONOTHERAPY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33947644114     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01377.x     Document Type: Article

References (42)

1. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
2. Martino R, Subira M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-82.
3. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115-21.
4. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-24.
5. Grow WB, Moreb JS, Roque D et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-19.
6. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission induction for acute myeloid leukemia: the pathogenic role of the antileukemic regimen. Clin Infect Dis 1995; 2: 361-9.
7. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
8. Lin SJ, Schranz J, Theutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
9. Reichenberger F, Habicht J, Matt P et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant 1999; 24: 1195-9.
10. Jantunen E, Piilonen A, Volin L et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000; 25: 867-71.
11. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-47.
12. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
13. Hebart H, Klingspor L, Klingebiehl T et al. PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: Preliminary results of a prospective study. Blood 2004; 104: 192 (Abstract 59a).
14. Slavin MA, Morrissey CO, Bradstock KF et al. A multicentre randomised controlled trial comparing two strategies for the diagnosis of invasive aspergillosis in high-risk haematology patients. http://www. clinicaltrials.gov [accessed on 31 August 2006].
15. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96.
16. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices and outcomes. 13 Aspergillus study group. Medicine 2000; 79: 250-60.
17. Bates D, Su L, Yu T et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93.
18. Leenders ACAP, Daene S, Jansen RLH et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-12.
19. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
20. Cornely O, Maertens J, Bresnik M et al. Liposomal Amphotericin B (L-AMB) as Initial Therapy for Invasive Filamentous Fungal Infections (IFFI): A Randomised Prospective Trial of a High Loading Regimen vs. Standard Dosing (AmBiLoad Trial). Poster No. 3222. 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10-13, 2005.
21. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005; 40: S392-400.
22. Walsh T, Patterson T, Langston A et al. Posacoanzole for Treatment of Invasive Aspergillosis in Patients who are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Blinded Trial. Abstract No. 682. 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003.
23. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single centre experience of 133 episodes in 116 patients. Br J Haematol 1994; 86: 754-60.
24. Ng TTC, Denning DW. Liposomal amphotericin B (Ambisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155: 1093-8.
25. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
26. Kartsonis NA, Saah AJ, Lipka CJ, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005; 50: 196-206.
27. Trenschel R, Ditschkowski M, Elmaagacli AH et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplant. Bone Marrow Transplant 2005; 35: 583-6.
28. Sable CA, Nguyen B-YT, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
29. Caspofungin acetate. FDA advisory committee meeting background. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3676b1_02.pdf [accessed on 31 August 2006].
30. Marr KA, Hachem R, Papanicolaou G et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004; 6: 110-6.
31. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13-20.
32. Marr KA, Glasmacher A, Sanz-Rodriguez C et al. Review of the Hepatic Safety Profile of 86 Patients Concomitantly Treated with Caspofungin and Cyclosporin A. Abstract No. 64. Focus on Fungal Infections 16, Las Vegas, NV, March 8-10, 2006.
33. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
34. Sullivan KM. Graft vs. host disease. In: Thomas ED, Blume KB, Forman SJ (eds), Hematopoietic Cell Transplantation, 2nd edn. Oxford: Blackwell Scientific Publications, 1999: 515.
35. Shulman HM, Sullivan KM, Weidan PL et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-17.
36. Denning D, Marinus A, Cohen J et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients. Diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37: 173-80.
37. Candoni A, Mestroni R, Damiani D et al. Caspofungin as first-line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 2005; 75: 227-33.
38. Glasmacher A, Cornely OA, Orlopp K et al. Caspofungin treatment in severely ill immunocompromised patients: a case-documentation study of 118 patients. J Antimicrob Chemother 2006; 57: 127-34.
39. Ascioglu S, de Pauw B, Bennett J et al. Analysis of Definitions Used in Clinical Research on Invasive Fungal Infections (IFI): Consensus for New Standardised Definitions. Abstract No. 1639. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29, 1999.
40. Furst S, Le QH, Piens MA et al. Systemic Fungal Infections (SFI) in Patients with Haematological Malignancy Treated by Voriconazole or Amphotericin B: Descriptive Analysis and Impact of Demographic Haematological and SFI Factors on Survival. Abstract No. 5534. 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003.
41. Maertens J, Glashmacher A, Selleslag D et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41: e9-14.
42. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter Non-comparative Study of Caspofungin Combined with other Antifungals in Adults with Invasive Aspergillosis Refractory to or Intolerant to Prior Therapy: Final Analysis. Abstract M-954. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., December 16-19, 2005.